COVID hinders HIV vaccine trial

HIV result.


THE coronavirus pandemic has had an impact on the upcoming phase one HIV vaccine trial in Zambia resulting in unanticipated delays in manufacturing and labelling of the vaccines. Speaking during a Science Media Café (MESICA) virtual meeting, Centre for Family Health Research in Zambia (CFHRZ) director William Kilembe said COVID-19 has slowed down the shipment of vaccines and reagents needed to commence the CORE 006 HIV vaccine trial. “COVID-19 has had an impact on HIV vaccine research. however, steps were implemented to limit the impact. COVID-19 has disturbed the fight against HIV and other public health problems and risks worsening these public health problems,” Dr Kilembe said. Dr Kilembe said the COVID-19 response should not sideline the HIV response through counselling, testing and treatment services as the HIV pandemic is still ongoing. He said activities have minimised at the three HIV vaccine clinical research sites in Lusaka and Ndola during the peak times of the COVID-19 pandemic. Dr Kilembe said lessons from the ongoing HIV vaccine research and development have been applied to expeditiously develop vaccines for COVID-19. “An ongoing HVTN 705 phase 2B HIV vaccine efficacy trial which enrolled 2,632 female participants at risk of HIV in five countries, namely Malawi, Zimbabwe, Mozambique, South Africa and Zambia, began the enrolment in 2017,” he said. The first participant in Zambia was enrolled in CLICK TO READ MORE

Facebook Feed